Urogynecology · Menopause
Genitourinary syndrome of menopause (GSM): the whole picture
GSM (formerly called vaginal atrophy) is progressive, chronic, and untreated in most women who have it. Unlike hot flashes, it doesn't improve on its own — it worsens. But vaginal estrogen is one of the most effective interventions in all of menopause medicine, with near-total safety and dramatic symptom reversal within 8–12 weeks.
The symptom map
- Vaginal dryness, burning, itching
- Painful intercourse (dyspareunia)
- Recurrent urinary tract infections
- Urinary urgency and frequency
- Post-coital bleeding or spotting
- Vulvar irritation and pain
Treatment options
- Vaginal estradiol cream, tablet, or ring — the gold standard
- Vaginal DHEA (Intrarosa) — for women preferring non-estrogen
- Ospemifene (Osphena) — oral SERM for those declining topical
- Non-hormonal moisturizers (Replens, hyaluronic acid) — helpful adjunct, not sufficient alone
- Vaginal laser therapy — evidence mixed, FDA-cautioned, not first-line
What Kindr does
Vaginal estrogen and DHEA prescriptions same-visit. We treat GSM aggressively because untreated GSM becomes a lifelong quality-of-life burden.
Frequently asked questions
What is GSM?
The collection of symptoms from estrogen loss in the vaginal, vulvar, and urinary tissues: dryness, burning, painful sex, urinary urgency, recurrent UTIs.
Does systemic HRT fix GSM?
Partially. Systemic HRT helps about 70% of GSM cases. The other 30% need topical vaginal estrogen added.
Is vaginal estrogen safe?
Yes, including for most breast cancer survivors after oncology consult. Systemic absorption is minimal and does not raise cancer or clot risk.
What about vaginal DHEA (Intrarosa)?
Prasterone (vaginal DHEA) is an alternative to estrogen — locally converted to estrogen and testosterone at the tissue level. Effective and non-systemic.
How fast does treatment work?
Symptoms improve at 4–8 weeks, full effect by 12 weeks. Ongoing use is required — stopping brings symptoms back.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.